A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

• Status: COMPLETED
• Trial end date: 2025-07-18

Summary

The purpose of this study is to measure the effect of multiple doses of AZD2389 on the pharmacokinetics (PK) of midazolam, caffeine, and bupropion in healthy participants.

• Phase: PHASE1

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Parexel
• Treatments: Bupropion; Caffeine; Midazolam